Plumbagin, isolated from plumbago zeylanica, induces cell death through apoptosis in human pancreatic cancer cells

Pancreatology

Volumn 9, Issue 6, 2009, Pages 797-809

  Chen, Chien An ^a   Chang, Hen Hong ^a   Kao, Chung Yu ^b   Tsai, Tung Hu ^d   Chen, Yu Jen ^c,e  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b MIN SHENG GENERAL HOSPITAL   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e CHINESE CULTURE UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Mitochondria; Pancreatic cancer; Plumbagin

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; CASPASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PLUMBAGIN; PROTEIN BAX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; CYTOSOL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; FLUOROMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NICK END LABELING; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; TUMOR XENOGRAFT; UPREGULATION; XENOGRAFT;

EID: 75149118296     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000210028     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
2. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
3. Li D, Xie K, Wolff R, Abbruzzese JL: Pancreatic cancer. Lancet 2004; 363: 1049-1057. (Pubitemid 38410779)
4. Kaufmann SH, Gores GJ: Apoptosis in cancer: cause and cure. Bioessays 2000; 22: 1007-1017.
5. Johnstone RW, Ruefli AA, Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164.
6. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, Ranzani GN: K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994; 54: 1556-1560. (Pubitemid 24106422)
7. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE: Tumor- suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57: 1731-1734. (Pubitemid 27199667)
8. Apple SK, Hecht JR, Lewin DN, Jahromi SA, Grody WW, Nieberg RK: Immunohistochemical evaluation of k-ras, p53, and HER- 2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. Human Pathol 1999; 30: 123-129.
9. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-489. (Pubitemid 27508237)
10. Prasad VS, Devi PU, Rao BS, Kamath R: Radiosensitizing effect of plumbagin on mouse melanoma cells grown in vitro. Indian J Exp Biol 1996; 34: 857-858. (Pubitemid 26289497)
11. Devi PU, Rao BS, Solomon FE: Effect of plumbagin on the radiation induced cytogenetic and cell cycle changes in mouse ehrlich ascites carcinoma in vivo. Indian J Exp Biol 1998; 36: 891-895. (Pubitemid 28417163)
12. Srinivas P, Gopinath G, Banerji A, Dinakar A, Srinivas G: Plumbagin induces reactive oxygen species, which mediate apoptosis in human cervical cancer cells. Mol Carcinog 2004; 40: 201-211. (Pubitemid 39056312)
13. Hsu YL, Cho CY, Kuo PL, Huang YT, Lin CC: Plumbagin (5-hydroxy-2-methyl- 1,4-naphthoquinone) induces apoptosis and cell cycle arrest in a549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther 2006; 318: 484-494.
14. Sandur SK, Ichikawa H, Sethi G, Ahn KS, Aggarwal BB: Plumbagin (5-hydroxy-2-methyl- 1,4-naphthoquinone) suppresses NF--B activation and NF--B-regulated gene products through modulation of p65 and I-B-kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. J Biol Chem 2006; 281: 17023-17033. (Pubitemid 43909506)
15. Okada H, Mak TW: Pathways of apoptotic and non-apoptotic death in tumour cells. Nature Rev 2004; 4: 592-603. (Pubitemid 39025054)
16. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995; 182: 1545-1556.
17. Fadok VA, de Cathelineau A, Daleke DL, Henson PM, Bratton DL: Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J Biol Chem 2001; 276: 1071-1077. (Pubitemid 32096530)
18. Fulda S, Debatin KM: Targeting apoptosis pathways in cancer therapy. Curr Cancer Drug Targets 2004; 4: 569-576. (Pubitemid 39536377)
19. Kroemer G, Reed JC: Mitochondrial control of cell death. Nature Med 2000; 6: 513-519. (Pubitemid 30305900)
20. Liu X, Kim CN, Yang J, Jemmerson R, Wang X: Induction of apoptotic program in cellfree extracts: requirement for datp and cytochrome c. Cell 1996; 86: 147-157. (Pubitemid 26256586)
21. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G: Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999; 397: 441-446. (Pubitemid 29078912)
22. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413. (Pubitemid 27251144)
23. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X: Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997; 90: 405-413. (Pubitemid 27347231)
24. Daugas E, Nochy D, Ravagnan L, Loeffler M, Susin SA, Zamzami N, Kroemer G: Apoptosis- inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. FEBS Lett 2000; 476: 118-123. (Pubitemid 30410801)
25. Bardeesy N, DePinho RA: Pancreatic cancer biology and genetics. Nature Rev 2002; 2: 897-909. (Pubitemid 37328891)
26. Jaffee EM, Hruban RH, Canto M, Kern SE: Focus on pancreas cancer. Cancer Cell 2002; 2: 25-28. (Pubitemid 41043985)
27. Kawesha A, Ghaneh P, Andren-Sandberg A, Ograed D, Skar R, Dawiskiba S, Evans JD, Campbell F, Lemoine N, Neoptolemos JP: Kras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 2000; 89: 469-474.
28. Dong M, Nio Y, Yamasawa K, Toga T, Yue L, Harada T: p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. J Surg Oncol 2003; 82: 111-120. (Pubitemid 36164446)
29. Duronio V, Scheid MP, Ettinger S: Downstream signalling events regulated by phosphatidylinositol 3-kinase activity. Cellular Signal 1998; 10: 233-239. (Pubitemid 28205901)
30. Perugini RA, McDade TP, Vittimberga FJ Jr, Callery MP: Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res 2000; 90: 39-44.
31. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA: The PI3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF- - B and c-Myc in pancreatic cancer cells. Oncogene 2004; 23: 8571-8580. (Pubitemid 39576463)
32. Ng SSW, Tsao MS, Chow S, Hedley DW: Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000; 60: 5451-5455.
33. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ: Inhibition of the phosphatidylinositol 3 - -kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002; 1: 989-997.
34. Manning BD: Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004; 167: 399-403.
35. Shah OJ, Wang Z, Hunter T: Inappropriate activation of the Tsc/Rheb/mTOR/S6K cassette induces irs1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004; 14: 1650-1656. (Pubitemid 39239362)